| Budget Amount *help |
¥18,980,000 (Direct Cost: ¥14,600,000、Indirect Cost: ¥4,380,000)
Fiscal Year 2015: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2013: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
|
|---|
| Outline of Final Research Achievements |
a) Structural simplification of muraymycins and caprazamycins have been investigated to develop analogues possessing antibacterial activity against drug-resistant bacteria such as MRSA and VRE with enough metabolic stability as well as reduced toxicity against human cells. b) Efficient synthetic strategy toward the synthesis of plusbacin A3, which is applicable to the synthesis of a range of analogues, has been developed. c) Total synthesis of quinaldopeptin has been developed via solid-phase synthesis. A range of analogues was synthesized and their antibacterial activity was evaluated to find a potent analogue with superior antibacterial activity than that of natural product.
|
